Google (GOOGL.US) spends $4.3 billions on electricity, securing 3,590 megawatts of long-term energy from Constellation Energy (CEG.US).
Google has signed a 3,590 MW power purchase agreement with Constellation Energy, with a quarter of the electricity coming from nuclear power, involving an investment of $4.3 billion.
According to Jinse Finance APP, Google (GOOGL.US) has signed a contract with Constellation Energy (CEG.US), the largest power grid operator in the United States, to purchase 3,590 megawatts of electricity, with newly built nuclear power accounting for about a quarter of this supply.
The two companies stated that the agreement will bring in more than $4.3 billion of new investment for Constellation and involves upgrading several nuclear reactors owned by the power company in the Midwest and Mid-Atlantic regions.
Large tech companies are racing to secure vast supplies of electricity across the United States to power data centers, reaching unprecedented agreements with American power companies.
In the past two years, Constellation announced an agreement to restart the Three Mile Island nuclear reactor in Pennsylvania to serve Microsoft’s data center, while Google signed a deal to restart NextEra Energy’s nuclear plant in Iowa.
In the latest package of arrangements, Google has signed a 20-year power purchase agreement to procure 890 megawatts of electricity from multiple Constellation-operated nuclear plants. These nuclear plants will be upgraded to produce more power from existing reactors.
The two companies stated that power from the first upgraded plant is expected to be delivered in 2028.
Google has also signed a long-term supply agreement to purchase an additional 2,700 megawatts of electricity from Constellation in the PJM region. Google noted that this portion of electricity is not tied to a specific source and is intended to provide long-term revenue certainty for Constellation’s operating plants.
Headquartered in Maryland, Constellation is the United States’ largest nuclear power plant operator and also owns a fleet of large natural gas power plants.
Amanda Peterson Corio, Google’s Global Head of Energy and Electricity, said in a statement, “We are committed to responsibly meeting our own growth, actively investing in clean, reliable electricity, and bringing new capacity to our country’s power grid.”
As part of the deal with Google, 11 nuclear units expected to be upgraded are located in Illinois, Pennsylvania, and New Jersey, within the coverage area of PJM Interconnection, the largest power grid in the United States.
PJM management has proposed that data center customers connected to the power grid in 13 states either provide their own electricity or face the risk of being remotely disconnected from the grid during peak usage times.
The two companies stated that the agreement between Google and Constellation is a direct response to PJM's “bring your own power” proposal.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Uber (UBER.US) plans to acquire ezCater for $2.3 billions in cash to expand corporate catering services
Uber (UBER.US) will acquire food service company ezCater Inc. for $2.3 billion in cash, a move that will help the Uber Eats delivery platform reach more corporate clients.
BUZZ - RPM shares drop as downgraded outlook overshadows Q1 earnings beat
October 6 – ** Paint manufacturer RPM International (RPM.N) shares fell 2% to close at $93.50 after releasing its first-quarter earnings report ** The company expects mid-single-digit growth in adjusted EBITDA for fiscal year 2027, compared to its previous forecast of 5% to 10% ** The company expects consolidated sales to achieve mid-single-digit growth, roughly in line with the previous estimate of 3% to 7% ** According to LSEG data, net sales for the first quarter were $2.22 billions, meeting analysts’ expectations ** Adjusted earnings per share for the first quarter were $1.98, higher than the expected $1.94 ** Out of 18 brokerages, 17 gave a “buy” or higher rating, 1 gave a “hold” rating; the median price target is $127.94—data compiled by LSEG ** As of the previous trading day’s close, the stock has fallen 8.37% year-to-date (To facilitate non-English speakers, Reuters has automated its reports into several other languages. As automated translations may contain errors or may lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them as a convenience to readers. Reuters assumes no liability for any harm or loss arising from the use of automatic translation functions.)
BUZZ - Stryker shares fall as long-time CEO Lobo steps down, with COO Styles set to succeed
October 6th - Stryker (SYK.N) shares fell more than 3% in pre-market trading to $275.44. Current President and Chief Operating Officer Spencer Stiles will succeed Kevin Lobo as the CEO of the medical device manufacturer. Lobo, who has served as CEO since 2012, will become Executive Chairman starting January 1. Lobo oversaw more than 60 acquisitions, including the purchase of robotic surgery company Mako, which helped transform the orthopedic sector. Out of 29 brokerage firms, 24 rate the stock as "buy" or higher, while 5 recommend "hold"; the median target price is $380, according to data compiled by LSEG. As of the previous trading day's close, the stock was down 18.85% year-to-date. (For the convenience of non-English speakers, Reuters has automated the translation of its report into several other languages. As automated translations may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters assumes no responsibility for any damages or losses arising from the use of automated translation features.)
BUZZ - ArriVent shares fall as its lung cancer drug fails to meet goals in late-stage clinical trial
On October 6, shares of drug developer ArriVent BioPharma (AVBP.O) dropped 62.7% to $10.62 in pre-market trading. The company stated that its experimental drug firmonertinib failed to significantly delay disease progression or death in a late-stage clinical trial involving 398 previously untreated patients with advanced lung cancer associated with a rare genetic mutation. In the higher-dose group, the median time patients lived without cancer progression was 11 months, compared to 9.5 months in the chemotherapy group; additionally, 60% of patients saw tumor shrinkage, versus 33% in the chemotherapy group. In the high-dose group, 52% of patients experienced serious side effects, compared to 55% in the chemotherapy group; no new safety issues were reported. ArriVent is reviewing the full results to determine the next steps for the drug's development. As of the previous trading day's close, AVBP had risen 41.5% so far this year. (For ease of use by non-English speakers, Reuters offers its reports translated automatically into several languages. Automated translations may be inaccurate or may not adequately convey the intended meaning. Reuters does not guarantee the accuracy of these translations and provides them solely for reader convenience. Reuters accepts no liability for any damages or losses incurred from the use of the automated translation service.)
Crypto prices
More
